Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity.

The staggering cost of bringing a drug to market coupled with the extremely high failure rate of prospective compounds in early phase clinical trials due to unexpected human toxicity makes it imperative that more relevant human models be developed to better predict drug toxicity. Drug-induced nephro...

詳細記述

書誌詳細
出版年:PLoS ONE
主要な著者: Teresa M DesRochers, Laura Suter, Adrian Roth, David L Kaplan
フォーマット: 論文
言語:英語
出版事項: Public Library of Science (PLoS) 2013-01-01
オンライン・アクセス:http://europepmc.org/articles/PMC3597621?pdf=render
_version_ 1852823059506921472
author Teresa M DesRochers
Laura Suter
Adrian Roth
David L Kaplan
author_facet Teresa M DesRochers
Laura Suter
Adrian Roth
David L Kaplan
author_sort Teresa M DesRochers
collection DOAJ
container_title PLoS ONE
description The staggering cost of bringing a drug to market coupled with the extremely high failure rate of prospective compounds in early phase clinical trials due to unexpected human toxicity makes it imperative that more relevant human models be developed to better predict drug toxicity. Drug-induced nephrotoxicity remains especially difficult to predict in both pre-clinical and clinical settings and is often undetected until patient hospitalization. Current pre-clinical methods of determining renal toxicity include 2D cell cultures and animal models, both of which are incapable of fully recapitulating the in vivo human response to drugs, contributing to the high failure rate upon clinical trials. We have bioengineered a 3D kidney tissue model using immortalized human renal cortical epithelial cells with kidney functions similar to that found in vivo. These 3D tissues were compared to 2D cells in terms of both acute (3 days) and chronic (2 weeks) toxicity induced by Cisplatin, Gentamicin, and Doxorubicin using both traditional LDH secretion and the pre-clinical biomarkers Kim-1 and NGAL as assessments of toxicity. The 3D tissues were more sensitive to drug-induced toxicity and, unlike the 2D cells, were capable of being used to monitor chronic toxicity due to repeat dosing. The inclusion of this tissue model in drug testing prior to the initiation of phase I clinical trials would allow for better prediction of the nephrotoxic effects of new drugs.
format Article
id doaj-art-36ae6b3d7e084bbca10a32793eb3bd7f
institution Directory of Open Access Journals
issn 1932-6203
language English
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
spelling doaj-art-36ae6b3d7e084bbca10a32793eb3bd7f2025-08-19T20:31:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0183e5921910.1371/journal.pone.0059219Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity.Teresa M DesRochersLaura SuterAdrian RothDavid L KaplanThe staggering cost of bringing a drug to market coupled with the extremely high failure rate of prospective compounds in early phase clinical trials due to unexpected human toxicity makes it imperative that more relevant human models be developed to better predict drug toxicity. Drug-induced nephrotoxicity remains especially difficult to predict in both pre-clinical and clinical settings and is often undetected until patient hospitalization. Current pre-clinical methods of determining renal toxicity include 2D cell cultures and animal models, both of which are incapable of fully recapitulating the in vivo human response to drugs, contributing to the high failure rate upon clinical trials. We have bioengineered a 3D kidney tissue model using immortalized human renal cortical epithelial cells with kidney functions similar to that found in vivo. These 3D tissues were compared to 2D cells in terms of both acute (3 days) and chronic (2 weeks) toxicity induced by Cisplatin, Gentamicin, and Doxorubicin using both traditional LDH secretion and the pre-clinical biomarkers Kim-1 and NGAL as assessments of toxicity. The 3D tissues were more sensitive to drug-induced toxicity and, unlike the 2D cells, were capable of being used to monitor chronic toxicity due to repeat dosing. The inclusion of this tissue model in drug testing prior to the initiation of phase I clinical trials would allow for better prediction of the nephrotoxic effects of new drugs.http://europepmc.org/articles/PMC3597621?pdf=render
spellingShingle Teresa M DesRochers
Laura Suter
Adrian Roth
David L Kaplan
Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity.
title Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity.
title_full Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity.
title_fullStr Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity.
title_full_unstemmed Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity.
title_short Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity.
title_sort bioengineered 3d human kidney tissue a platform for the determination of nephrotoxicity
url http://europepmc.org/articles/PMC3597621?pdf=render
work_keys_str_mv AT teresamdesrochers bioengineered3dhumankidneytissueaplatformforthedeterminationofnephrotoxicity
AT laurasuter bioengineered3dhumankidneytissueaplatformforthedeterminationofnephrotoxicity
AT adrianroth bioengineered3dhumankidneytissueaplatformforthedeterminationofnephrotoxicity
AT davidlkaplan bioengineered3dhumankidneytissueaplatformforthedeterminationofnephrotoxicity